Outcomes in 125 individuals with adrenal incidentalomas from a single centre. A retrospective assessment of the 1mg overnight and low dose dexamethasone suppression tests

Hormone and Metabolic Research

Volumn 43, Issue 13, 2011, Pages 962-969

  Theodoraki, A ^a   Khoo, B ^a   Hamda, A ^a   Schwappach, A ^a   Perera, S ^a   Vanderpump, M P J ^a   Bouloux, P M ^a  

^a ROYAL FREE LONDON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

adrenal adenoma; Cushings syndrome; hypercortisolism

Indexed keywords

DEXAMETHASONE; HYDROCORTISONE;

ABDOMINAL PAIN; ADRENAL CORTEX CARCINOMA; ADRENAL HYPERPLASIA; ADRENAL INCIDENTALOMA; ADRENAL METASTASIS; ADRENALECTOMY; ADULT; ARTICLE; CLINICAL ASSESSMENT; CLINICAL FEATURE; CUSHING SYNDROME; DEXAMETHASONE SUPPRESSION TEST; DIAGNOSTIC IMAGING; FALSE POSITIVE RESULT; FEMALE; HISTOPATHOLOGY; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYDROCORTISONE RELEASE; HYPERCORTISOLISM; HYPERTENSION; IMMUNOASSAY; INCIDENTAL FINDING; KIDNEY CARCINOMA; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OUTCOME ASSESSMENT; PHEOCHROMOCYTOMA; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL; TUMOR VOLUME;

ADRENAL GLAND NEOPLASMS; AGED; DEXAMETHASONE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 83155180276     PISSN: 00185043     EISSN: 14394286     Source Type: Journal    
DOI: 10.1055/s-0031-1291249     Document Type: Article

References (35)

1. NIH state-of-the-science statement on management of the clinically inapparent adrenal mass (incidentaloma). NIH Consens State Sci Statements: 2002; 19 1 25
2. Zeiger M A, Thompson G B, Duh Q Y, Hamrahian A H, Angelos P, Elaraj D, Fishman E, Kharlip J. The American Association of Clinical Endocrinologists and American Association of Endocrine Surgeons medical guidelines for the management of adrenal incidentalomas. Endocr Pract: 2009; 15 01 1 20
3. Nieman L K. Approach to the patient with an adrenal incidentaloma. J Clin Endocrinol Metab: 2010; 95 4106 4113
4. Young W F Jr. Clinical practice. The incidentally discovered adrenal mass. N Engl J Med: 2007; 356 601 610 (Pubitemid 46220820)
5. Cawood T J, Hunt P J, OShea D, Cole D, Soule S. Recommended evaluation of adrenal incidentalomas is costly, has high false-positive rates and confers a risk of fatal cancer that is similar to the risk of the adrenal lesion becoming malignant; time for a rethink? Eur J Endocrinol: 2009; 161 513 527
6. Stewart P M. Is subclinical Cushings syndrome an entity or a statistical fallout from diagnostic testing? Consensus surrounding the diagnosis is required before optimal treatment can be defined. J Clin Endocrinol Metab: 2010; 95 2618 2620
7. Comlekci A, Yener S, Ertilav S, Secil M, Akinci B, Demir T, Kebapcilar L, Bayraktar F, Yesil S, Eraslan S. Adrenal incidentaloma, clinical, metabolic, follow-up aspects: single centre experience. Endocrine: 2010; 37 40 46
8. Tauchmanova L, Rossi R, Biondi B, Pulcrano M, Nuzzo V, Palmieri E A, Fazio S, Lombardi G. Patients with subclinical Cushings syndrome due to adrenal adenoma have increased cardiovascular risk. J Clin Endocrinol Metab: 2002; 87 4872 4878 (Pubitemid 35316318)
9. Mazzuco T L, Bourdeau I, Lacroix A. Adrenal incidentalomas and subclinical Cushings syndrome: diagnosis and treatment. Curr Opin Endocrinol Diabetes Obes: 2009; 16 203 210
10. Nieman L K, Biller B M, Findling J W, Newell-Price J, Savage M O, Stewart P M, Montori V M. The diagnosis of Cushings syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab: 2008; 93 1526 1540 (Pubitemid 351656485)
11. Masserini B, Morelli V, Bergamaschi S, Ermetici F, Eller-Vainicher C, Barbieri A M, Maffini M A, Scillitani A, Ambrosi B, Beck-Peccoz P, Chiodini I. The limited role of midnight salivary cortisol levels in the diagnosis of subclinical hypercortisolism in patients with adrenal incidentaloma. Eur J Endocrinol: 2009; 160 87 92
12. Eller-Vainicher C, Morelli V, Salcuni A S, Battista C, Torlontano M, Coletti F, Iorio L, Cuttitta A, Ambrosio A, Vicentini L, Pellegrini F, Copetti M, Beck-Peccoz P, Arosio M, Ambrosi B, Trischitta V, Scillitani A. Accuracy of several parameters of hypothalamic-pituitary-adrenal axis activity in predicting before surgery the metabolic effects of the removal of an adrenal incidentaloma. Eur J Endocrinol: 2010; 163 925 935
13. Chiodini I, Morelli V, Salcuni A S, Eller-Vainicher C, Torlontano M, Coletti F, Iorio L, Cuttitta A, Ambrosio A, Vicentini L, Pellegrini F, Copetti M, Beck-Peccoz P, Arosio M, Ambrosi B, Trischitta V, Scillitani A. Beneficial metabolic effects of prompt surgical treatment in patients with an adrenal incidentaloma causing biochemical hypercortisolism. J Clin Endocrinol Metab: 2010; 95 2736 2745
14. Garrapa G G, Pantanetti P, Arnaldi G, Mantero F, Faloia E. Body composition and metabolic features in women with adrenal incidentaloma or Cushings syndrome. J Clin Endocrinol Metab: 2001; 86 5301 5306 (Pubitemid 33070251)
15. Terzolo M, Pia A, Ali A, Osella G, Reimondo G, Bovio S, Daffara F, Procopio M, Paccotti P, Borretta G, Angeli A. Adrenal incidentaloma: a new cause of the metabolic syndrome? J Clin Endocrinol Metab: 2002; 87 998 1003 (Pubitemid 36121054)
16. Chiodini I, Morelli V, Masserini B, Salcuni A S, Eller-Vainicher C, Viti R, Coletti F, Guglielmi G, Battista C, Carnevale V, Iorio L, Beck-Peccoz P, Arosio M, Ambrosi B, Scillitani A. Bone mineral density, prevalence of vertebral fractures, and bone quality in patients with adrenal incidentalomas with and without subclinical hypercortisolism: an Italian multicenter study. J Clin Endocrinol Metab: 2009; 94 3207 3214
17. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA: 2001; 285 2486 2497
18. American Diabetes Association Diagnosis and classification of diabetes mellitus. Diabetes Care: 2010; 33 01 S62 S69
19. Funder J W, Carey R M, Fardella C, Gomez-Sanchez C E, Mantero F, Stowasser M, Young W F, Montori V M. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab: 2008; 93 3266 3281
20. Aron D C, Raff H, Findling J W. Effectiveness versus efficacy: the limited value in clinical practice of high dose dexamethasone suppression testing in the differential diagnosis of adrenocorticotropin-dependent Cushings syndrome. J Clin Endocrinol Metab: 1997; 82 1780 1785 (Pubitemid 127495186)
21. Hamrahian A H, Ioachimescu A G, Remer E M, Motta-Ramirez G, Bogabathina H, Levin H S, Reddy S, Gill I S, Siperstein A, Bravo E L. Clinical utility of noncontrast computed tomography attenuation value (hounsfield units) to differentiate adrenal adenomas/hyperplasias from nonadenomas: Cleveland Clinic experience. J Clin Endocrinol Metab. 2005; 90 871 877 (Pubitemid 40279211)
22. Valassi E, Swearingen B, Lee H, Nachtigall L B, Donoho D A, Klibanski A, Biller B M. Concomitant medication use can confound interpretation of the combined dexamethasone-corticotropin releasing hormone test in Cushings syndrome. J Clin Endocrinol Metab: 2009; 94 4851 4859
23. Ehrhart-Bornstein M, Hinson J P, Bornstein S R, Scherbaum W A, Vinson G P. Intraadrenal interactions in the regulation of adrenocortical steroidogenesis. Endocr Rev: 1998; 19 101 143 (Pubitemid 29114288)
24. Yi D W, Kim S Y, Shin D H, Kang Y H, Son S M. Pheochromocytoma crisis after a dexamethasone suppression test for adrenal incidentaloma. Endocrine: 2010; 37 213 219
25. Rosas A L, Kasperlik-Zaluska A A, Papierska L, Bass B L, Pacak K, Eisenhofer G. Pheochromocytoma crisis induced by glucocorticoids: a report of four cases and review of the literature. Eur J Endocrinol: 2008; 158 423 429 (Pubitemid 351405009)
26. Pecori Giraldi F, Ambrogio A G, De Martin M, Fatti L M, Scacchi M, Cavagnini F. Specificity of first-line tests for the diagnosis of Cushings syndrome: assessment in a large series. J Clin Endocrinol Metab: 2007; 92 4123 4129 (Pubitemid 350074721)
27. Martin N M, Dhillo W S, Banerjee A, Abdulali A, Jayasena C N, Donaldson M, Todd J F, Meeran K. Comparison of the dexamethasone-suppressed corticotropin-releasing hormone test and low-dose dexamethasone suppression test in the diagnosis of Cushings syndrome. J Clin Endocrinol Metab: 2006; 91 2582 2586 (Pubitemid 44024621)
28. Nieman L. Editorial: The dexamethasone-suppressed corticotropin-releasing hormone test for the diagnosis of Cushings syndrome: what have we learned in 14 years? J Clin Endocrinol Metab: 2007; 92 2876 2878 (Pubitemid 47236343)
29. Newell-Price J, Bertagna X, Grossman A B, Nieman L K. Cushings syndrome. Lancet: 2006; 367 9522 1605 1617
30. Muscogiuri G, Sorice G P, Prioletta A, Mezza T, Cipolla C, Salomone E, Giaccari A, Pontecorvi A, Della Casa S. The size of adrenal incidentalomas correlates with insulin resistance. Is there a cause-effect relationship? Clin Endocrinol (Oxf): 2011; 74 300 305
31. Bernini G, Moretti A, Iacconi P, Miccoli P, Nami R, Lucani B, Salvetti A. Anthropometric, haemodynamic, humoral and hormonal evaluation in patients with incidental adrenocortical adenomas before and after surgery. Eur J Endocrinol: 2003; 148 213 219 (Pubitemid 36305687)
32. Toniato A, Merante-Boschin I, Opocher G, Pelizzo M R, Schiavi F, Ballotta E. Surgical versus conservative management for subclinical Cushing syndrome in adrenal incidentalomas: a prospective randomized study. Ann Surg: 2009; 249 388 391
33. Castro M, Elias P C, Quidute A R, Halah F P, Moreira A C. Out-patient screening for Cushings syndrome: the sensitivity of the combination of circadian rhythm and overnight dexamethasone suppression salivary cortisol tests. J Clin Endocrinol Metab: 1999; 84 878 882 (Pubitemid 29138212)
34. Barzon L, Fallo F, Sonino N, Boscaro M. Overnight dexamethasone suppression of cortisol is associated with radiocholesterol uptake patterns in adrenal incidentalomas. Eur J Endocrinol: 2001; 145 223 224 (Pubitemid 32707610)
35. Vassilatou E, Vryonidou A, Michalopoulou S, Manolis J, Caratzas J, Phenekos C, Tzavara I. Hormonal activity of adrenal incidentalomas: results from a long-term follow-up study. Clin Endocrinol (Oxf): 2009; 70 674 679